Comparative effects of sirolimus and cyclosporin on conduit arteries endothelial function in kidney recipients

Transpl Int. 2010 Nov;23(11):1135-43. doi: 10.1111/j.1432-2277.2010.01122.x.

Abstract

This study attempted to establish whether a calcineurin inhibitor (CNI)-free immunosuppressant regimen based on sirolimus (SRL) is associated with a preservation of conduit arteries endothelial function in kidney recipients or not. Twenty-nine kidney recipients were randomized to receive since transplantation SRL (n=15) or cyclosporin A (CsA, n=14) associated with mycophenolate mofetil (MMF) and steroids (6months) in a parallel prospective study. Systolic, diastolic blood pressures, glomerular filtration rate (GFR) and radial artery flow-mediated dilatation (FMD) induced by postischaemic hyperaemia were assessed in a blind manner at one (M1) and 7months (M7) after transplantation. Endothelium-independent dilatation was assessed by glyceryl trinitrate spray. There was no difference between the groups for all vascular parameters at M1. At M7, systolic blood pressure was lower (SRL: 119±3 vs. CsA: 138±4mmHg, P<0.05) and FMD was higher in SRL compared with CsA (SRL: 13.1±0.9 vs. CsA: 9.9±0.9%, P<0.05) without any difference for hyperaemia, endothelium-independent dilatation and GFR (SRL: 66.7±1.05 vs. CsA: 67.5±1.22ml/min). Our results demonstrate that a CNI-free regimen based on SRL and MMF prevents conduit artery endothelial dysfunction compared with CsA and MMF in kidney recipients suggesting a beneficial arterial wall effect that may also contribute to the decrease in systolic blood pressure.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Arteries / drug effects
  • Blood Pressure
  • Cyclosporine / therapeutic use*
  • Endothelium, Vascular / drug effects*
  • Female
  • Glomerular Filtration Rate
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Ischemia / pathology
  • Kidney / drug effects
  • Kidney Transplantation / adverse effects
  • Kidney Transplantation / methods
  • Male
  • Middle Aged
  • Prospective Studies
  • Sirolimus / therapeutic use*
  • Time Factors

Substances

  • Immunosuppressive Agents
  • Cyclosporine
  • Sirolimus